---
title: "Teva Canada Limited, Medincell's Affiliate, Gains Canadian Approval for Risperidone LAI for Schizophrenia Treatment"
description: "Teva Canada Limited, an affiliate of Medincell’s partner Teva Pharmaceutical Industries Ltd., has received regulatory approval from Health Canada for risperidone LAI, a treatment for schizophrenia in "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/258572722.md"
published_at: "2025-09-23T17:26:05.000Z"
---

# Teva Canada Limited, Medincell's Affiliate, Gains Canadian Approval for Risperidone LAI for Schizophrenia Treatment

> Teva Canada Limited, an affiliate of Medincell’s partner Teva Pharmaceutical Industries Ltd., has received regulatory approval from Health Canada for risperidone LAI, a treatment for schizophrenia in adults. This approval marks a significant development in the pharmaceutical sector, enhancing treatment options for patients with schizophrenia.

Teva Canada Limited, an affiliate of Medincell’s partner Teva Pharmaceutical Industries Ltd., has received regulatory approval for risperidone LAI from Health Canada for the treatment of schizophrenia in adults. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medincell SA published the original content used to generate this news brief on September 23, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [TEVA.US - Teva Pharmaceutical Industries](https://longbridge.com/en/quote/TEVA.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Teva Submits FDA Application for Once-Monthly Olanzapine LAI for Schizophrenia | Teva Pharmaceutical Industries Ltd. has submitted a New Drug Application to the FDA for its once-monthly olanzapine LAI  | [Link](https://longbridge.com/en/news/269089263.md) |
| Teva And Medincell’S Risperidone Lai Approved In Canada As Longavo® | Medincell SA :TEVA AND MEDINCELL’S RISPERIDONE LAI APPROVED IN CANADA AS LONGAVO® | [Link](https://longbridge.com/en/news/258564935.md) |
| Galderma Expands Restylane® Portfolio in Japan With Launch of OBT™ Hyaluronic Acid Injectables Restylane Defyne™ and Refyne™ | Galderma has launched Restylane Defyne and Refyne, the first Optimal Balance Technology (OBT) hyaluronic acid injectable | [Link](https://longbridge.com/en/news/275559104.md) |
| Shenhua Energy Gets Securities Regulator's Nod for Share Placement Plan | Shenhua Energy Gets Securities Regulator's Nod for Share Placement Plan | [Link](https://longbridge.com/en/news/275851575.md) |
| Hemogenyx Raises £2.5m to Advance CAR-T Trials in Adult and Pediatric AML | HemoGenyx Pharmaceuticals has raised £2.5 million from private investors through a direct subscription for new shares, f | [Link](https://longbridge.com/en/news/275486211.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.